National Clinical Trial for Treatment of Advanced Prostate Cancer Available in Southwest Florida
21st Century Oncology offers clinical trials in Southwest Florida.
Fort Myers, FL, October 15, 2011 --(PR.com)-- Local men with advanced prostate cancer can now access groundbreaking research for treatment that would otherwise only be available at esteemed academic centers. 21st Century Oncology, a national leader in development and operation of radiation oncology centers headquartered in Fort Myers, is participating in the National Urology and Radiation Oncology clinical trials program.
The most current research study being conducted at 21st Century Oncology is the Provenge® study, a drug produced by Dendreon Corporation. This immunotherapy method is designed to use the body’s own immune system to fight of prostate cancer. Provenge has been proven to induce durable remission and will be offered to the public in the form of a research trial called “PROCEED Registry.” 21st Century Oncology is initiating the PROCEED Registry and engaging with several other industry leaders in all phase three pipeline therapeutics that effect prostate cancer patients.
“A growing amount of clinical data suggests that Provenge may be able to provide benefit to men with advanced prostate cancer,” says Dr. Neal Shore, Director of Urology at 21st Century Oncology. “Prostate cancer patients have long been in need of treatment options that can provide a disease free and pain free way of life after cancer.”
About 21st Century Oncology
Headquartered in Fort Myers, 21st Century Oncology, LLC. is a leading developer and operator of radiation therapy centers in the U.S. For 30 years, 21st Century Oncology has been committed to providing premier, quality, cost-effective radiation therapy services that are responsive to the needs of its patients through continuous improvement and innovation. The company employs over 113 radiation oncologists and over 138 specialists, including 84 urologists, 28 surgeons, 15 medical oncologists, 3 pathologists, 4 gynecologic oncologists and 4 primary care physicians. They operate 94 facilities in 16 states in the USA with another 27 internationally for a total of 121 facilities.
###
For further information, contact:
Sherri Kubesh, 239-839-6015 cell, or skubesh@rtsx.com
The most current research study being conducted at 21st Century Oncology is the Provenge® study, a drug produced by Dendreon Corporation. This immunotherapy method is designed to use the body’s own immune system to fight of prostate cancer. Provenge has been proven to induce durable remission and will be offered to the public in the form of a research trial called “PROCEED Registry.” 21st Century Oncology is initiating the PROCEED Registry and engaging with several other industry leaders in all phase three pipeline therapeutics that effect prostate cancer patients.
“A growing amount of clinical data suggests that Provenge may be able to provide benefit to men with advanced prostate cancer,” says Dr. Neal Shore, Director of Urology at 21st Century Oncology. “Prostate cancer patients have long been in need of treatment options that can provide a disease free and pain free way of life after cancer.”
About 21st Century Oncology
Headquartered in Fort Myers, 21st Century Oncology, LLC. is a leading developer and operator of radiation therapy centers in the U.S. For 30 years, 21st Century Oncology has been committed to providing premier, quality, cost-effective radiation therapy services that are responsive to the needs of its patients through continuous improvement and innovation. The company employs over 113 radiation oncologists and over 138 specialists, including 84 urologists, 28 surgeons, 15 medical oncologists, 3 pathologists, 4 gynecologic oncologists and 4 primary care physicians. They operate 94 facilities in 16 states in the USA with another 27 internationally for a total of 121 facilities.
###
For further information, contact:
Sherri Kubesh, 239-839-6015 cell, or skubesh@rtsx.com
Contact
21st Century Oncology
Carolyn Rogers
239-278-3900
Carolyn Rogers
239-278-3900
Contact
Categories